Advertisement

Topics

Double-blind Comparative Study of SYR-322-MET.

2014-11-26 07:15:23 | BioPortfolio

Published on BioPortfolio: 2014-11-26T07:15:23-0500

Clinical Trials [4972 Associated Clinical Trials listed on BioPortfolio]

Metformin Hydrochloride in Treating Patients With Early-Stage Breast Cancer

RATIONALE: Metformin hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This randomized phase III trial is studying how well...

Bioequivalence Study of Metformin Hydrochloride 1000mg Tablets Under Fed Conditions

The objective of this study was to evaluate the relative bioavailability of the test formulation of metformin hydrochloride 1000 mg tablets with an already marketed reference formulation G...

Bioequivalence Study of Metformin Hydrochloride 1000mg Tablets Under Fasting Conditions

The objective of this study was to evaluate the relative bioavailability of the test formulation of metformin hydrochloride 1000 mg tablets with an already marketed reference formulation G...

Food Study Metformin Hydrochloride ER Tablets 750 mg and Glucophage XR 750 mg

The objective of this study was to investigate the bioequivalence of Mylan's metformin hydrochloride ER tablets to Bristol-Myers Squibb's Glucophage® XR tablets following a single, oral 7...

Food BE Study Metformin Hydrochloride ER Tablets 500 mg and Glucophage XR 500 mg

The objective of this study was to investigate the bioequivalence of Mylan's metformin hydrochloride ER tablets to Bristol-Myers Squibb's Glucophage® XR tablets following a single, oral 5...

PubMed Articles [4839 Associated PubMed Articles listed on BioPortfolio]

Assessment of Taste and Grittiness of Riomet ER Strawberry, Riomet ER Grape, Riomet Cherry, and Metformin Immediate-Release Tablets in Healthy Subjects.

This study was conducted to evaluate the taste and grittiness of two formulations of Riomet ER (metformin hydrochloride for extended release [ER] oral suspension 100 mg/mL) differing only in their fl...

Transdermal Delivery of Metformin Hydrochloride from a Semisolid Vehicle.

Metformin hydrochloride is a traditional, FDA-approved drug used as a first-line drug of choice to treat type 2 diabetes. Research has shown metformin hydrochloride effective in injuries, including ag...

Differential effects of metformin glycinate and hydrochloride in glucose production, AMPK phosphorylation and insulin sensitivity in hepatocytes from non-diabetic and diabetic mice.

The liver is a main target tissue of the biguanide metformin which activates AMP-activated protein kinase (AMPK). We have previously reported that administration of metformin glycinate showed a greate...

Prolonged release of metformin by SiO nanoparticles pellets for type II diabetes control.

Mesoporous silica nanoparticles (MSNPs) were synthesized and loaded with metformin hydrochloride (Metf), its adsorption has studied at different concentrations and pHs, optimal adsorption conditions w...

Improved glycemic control with minimal systemic metformin exposure: Effects of Metformin Delayed-Release (Metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes.

Metformin use is restricted in patients with renal impairment due to potential excess systemic accumulation. This study evaluated the glycemic effects and safety of metformin delayed-release (Metformi...

Medical and Biotech [MESH] Definitions

A pharmaceutical preparation of sitagliptin phosphate and metformin hydrochloride that is used in the treatment of TYPE 2 DIABETES.

A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)

An analog of GLUCAGON-LIKE PEPTIDE 1 and agonist of the GLUCAGON-LIKE PEPTIDE 1 RECEPTOR that is used as a HYPOGLYCEMIC AGENT and supplemental therapy in the treatment of DIABETES MELLITUS by patients who do not respond to METFORMIN.

A thiophene derivative and selective NEUROTRANSMITTER UPTAKE INHIBITOR for SEROTONIN and NORADRENALINE (SNRI). It is an ANTIDEPRESSIVE AGENT and ANXIOLYTIC, and is also used for the treatment of pain in patients with DIABETES MELLITUS and FIBROMYALGIA.

A biguanide hypoglycemic agent with actions and uses similar to those of METFORMIN. Although it is generally considered to be associated with an unacceptably high incidence of lactic acidosis, often fatal, it is still available in some countries. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290)

More From BioPortfolio on "Double-blind Comparative Study of SYR-322-MET."

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial